EMBT Stock Overview
Operates as a clinical stage biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Ember Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.67% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| EMBT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 4.2% | 2.0% |
| 1Y | n/a | 13.7% | 32.4% |
Return vs Industry: Insufficient data to determine how EMBT performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how EMBT performed against the US Market.
Price Volatility
| EMBT volatility | |
|---|---|
| EMBT Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EMBT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EMBT's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Joe Hernandez | www.embertx.com |
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company focuses on the clinical application of bone morphogenetic protein-7 (BMP-7) to develop regenerative medicines for the disease modification of osteoarthritis (OA), reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases, such as chronic kidney disease (CKD) and Alport’s syndrome, as well as metabolic diseases, including obesity and type 2 diabetes. Its lead BMP-7 product candidates include MT-006, which has completed Phase 2a clinical trial for targeting OA; MT-007 that has completed Preclinical trial for CKD and Alport syndrome; MT-008, a Preclinical trial completed candidate for Alport syndrome; and MT-009, a Preclinical trial completed candidate for metabolic disease.
Ember Therapeutics, Inc. Fundamentals Summary
| EMBT fundamental statistics | |
|---|---|
| Market cap | US$43.00 |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs EMBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMBT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EMBT perform over the long term?
See historical performance and comparison